PIXIMUNE, INC.

Biotech · Private

Immunotherapy targeting cytotoxic photoreceptor debris in retinitis pigmentosa to prevent secondary retinal cell death

Grants
$307K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Antibody-based gene-agnostic treatment for inherited retinal degeneration$306,814
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2115BRIACELL THERAPEUTICS CORP—$34M
2116General Folders Inc.—$20K
2117Renasant Bio—$55M
2118PIXIMUNE, INC.——
2119DFI Holding Inc.—$55M
2120Sonoma Biotherapeutics—$265M
2121ARVINAS, INC.—$129M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.